McKesson (MCK)
(Delayed Data from NYSE)
$485.42 USD
+3.15 (0.65%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $485.43 +0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$485.42 USD
+3.15 (0.65%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $485.43 +0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth D Momentum B VGM
Zacks News
Veeva Systems' (VEEV) New Launch to Streamline Clinical Data
by Zacks Equity Research
Veeva Systems' (VEEV) new offering is expected to speed up the aggregation and cleaning of clinical trial data, thereby making it usable.
Abbott's (ABT) Q3 Earnings Top Estimates, 2022 EPS View Up (Revised)
by Zacks Equity Research
Abbott's (ABT) Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.
IDEXX (IDXX) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
IDEXX's (IDXX) CAG premium instrument placements are expected to have recorded significant growth in Q3 on the continued rise in Catalyst and premium hematology placements.
STERIS (STE) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
STERIS' (STE) Dental arm revenues are expected to have been impacted somewhat by supply chain challenges.
Abbott's (ABT) Q2 Earnings Top Estimates, 2022 EPS View Up
by Zacks Equity Research
Abbott's (ABT) Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.
Intuitive Surgical (ISRG) Q3 Earnings Beat, Procedures Recover
by Zacks Equity Research
Intuitive Surgical's (ISRG) third-quarter results reflect health demand for procedures, partially offset by lower system sales and unfavorable currency.
Veeva Systems' (VEEV) New Launch to Enhance Digital Trials
by Zacks Equity Research
Veeva Systems' (VEEV) new offering is expected to meet the requirements of patients, sites and sponsors, thereby streamlining trial activities.
BD (BDX)-Biocorp's Latest Deal to Enhance Tracking Adherence
by Zacks Equity Research
BD's (BDX) newest agreement is expected to enable the care provision to transition to alternate settings and improve chronic disease outcomes.
3 Reasons to Retain Ecolab (ECL) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Ecolab (ECL) owing to its strong business.
Bio-Rad (BIO) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Owing to the impact of the Russia-Ukraine war situation, supply chain constraints, as well as the inflationary situation, we expect Bio-Rad's (BIO) Life Science arm to experience a year-over-year decline.
Reasons to Retain West Pharmaceutical (WST) in Your Portfolio
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex woes persist.
What's in Store for Edwards Lifesciences (EW) in Q3 Earnings?
by Zacks Equity Research
Within the TAVR arm, Edwards Lifesciences (EW) is likely to have witnessed continued growth in procedures across the United States and worldwide.
Align Technology (ALGN) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Align Technology's (ALGN) Invisalign First for kids is gaining market share rapidly across all regions.
Grab These Top 4 Defensive Stocks to Beat the Market Doldrums
by Snehadri Nag
Here we mention four defensive stocks, namely Lamb Weston (LW), Consolidated Water (CWCO), Archer Daniels Midland (ADM) and McKesson (MCK) with strong prospects to beat the market volatility.
Should JPMorgan Diversified Return U.S. Equity ETF (JPUS) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JPUS
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Will Boston Scientific (BSX) Beat Q3 Earnings Estimates?
by Zacks Equity Research
Boston Scientific's (BSX) top line is likely to have improved with non-COVID elective medical procedures running in a full-fledged way in the United States and across the globe.
What's in Store for Thermo Fisher (TMO) in Q3 Earnings?
by Zacks Equity Research
In terms of performance in high-growth and emerging markets, in its flagship facility for cell culture media in Grand Island, NY, Thermo Fisher (TMO) completes capacity expansion.
3 Reasons to Add Inogen (INGN) Stock to Your Portfolio Now
by Zacks Equity Research
Investors continue to be optimistic about Inogen (INGN) on its potential in the POC space and a strong product portfolio.
LabCorp (LH) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
LabCorp's (LH) growth in early development and clinical development are expected to have been offset by central labs on the account of a significant slowdown in COVID-related work.
Is a Beat Likely for Intuitive Surgical (ISRG) in Q3 Earnings?
by Zacks Equity Research
Intuitive Surgical's (ISRG) third-quarter results are likely to reflect solid performance in the Instruments & Accessories segment. However, rising costs may have hurt margins.
Nevro (NVRO) Gains Following FDA Approval for Senza HFX iQ
by Zacks Equity Research
Nevro (NVRO) gets FDA approval for its next-generation SCS system, Senza HFX iQ, for treating chronic back and leg pain.
Quest Diagnostics (DGX) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
The non-COVID base business is expected to have gained from Quest Diagnostics' (DGX) efforts to expand value-based contracts with payers.
Reasons to Retain Merit Medical (MMSI) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Merit Medical (MMSI) owing to its strong product portfolio.
Accuray's (ARAY) New Treatment Package to Boost Patient Outcome
by Zacks Equity Research
Accuray's (ARAY) latest automated breast cancer treatment package for the Radixact System is expected to extend and improve the quality of patients' lives.